ISPOR - Session

Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings

May 6, 2024, 11:30 AM